Ongericimab is a monoclonal antibody commercialized by Shanghai Junshi Bioscience, with a leading Phase I program in Transitional Cell Cancer (Urothelial Cell Cancer). According to Globaldata, it is involved in 8 clinical trials, of which 3 were completed, 4 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Ongericimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Ongericimab is expected to reach an annual total of $14 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Ongericimab Overview

Ongericimab (JS-002) is under development for the treatment of homozygous familial hypercholesterolemia, heterozygous non-familial and familial hypercholesterolemia, hyperlipidemia, mixed dyslipidemia and hepatocellular carcinoma, lung cancer, transitional cell cancer (urothelial cell cancer). The drug candidate is administered by subcutaneous and intravenous route. It acts by targeting proprotein convertase subtilisin kexin 9 (PCSK9).

Shanghai Junshi Bioscience Overview

Shanghai Junshi Bioscience (Junshi Bioscience) is a biopharmaceutical company that discovers, develops and commercializes drugs for infectious diseases, oncology, metabolic, auto-immunity and neurologic indications. It is investigating JS001 antibody against various malignant tumors; JS003, JS006, and JS201 to treat solid tumors; JS004 for melanoma, hodgkin lymphoma and lung carcinoma; JS101 for the treatment of breast cancer; JS108 for pancreatic, triple negative breast cancer, small cell lung cancer. The company is also evaluating JS002 against hyperlipidaemia; JS103 for hyperuricacidemia and gout disease; UPB1211 to treat rheumatoid arthritis, ankylosing spondylitis, and psoriasis arthritis; JS010 for migraine; and JS016 against COVID-19. It operates with research and development centers in California and Maryland, the US. Junshi Bioscience is headquartered in Shanghai, China.

The company reported revenues of (Renminbi) CNY4,024.8 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of CNY1,594.9 million in FY2020. The operating loss of the company was CNY570.8 million in FY2021, compared to an operating loss of CNY1,640.1 million in FY2020. The net loss of the company was CNY718.6 million in FY2021, compared to a net loss of CNY1,665.6 million in FY2020.

For a complete picture of Ongericimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.